A Clinical Trial to Investigate a New Treatment for Advanced Lung Cancer
Phase 1/2
594
about 6.2 years
18+
15 sites in AZ, CA, FL +7
What this study is about
This trial is testing the safety and effectiveness of a new combination treatment with BNT324 and BNT327 in people with advanced lung cancer. The treatment involves taking medication, and it will last about 2 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive BNT324
- 2.Receive BNT327
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part 1 - Occurrence of Treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by dose level, Part 1 - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs by dose level, Part 2 cohorts 1 and 2 - Objective response rate (ORR) by cohort and treatment arm, Part 2 cohorts 1 and 2 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment arm, Part 2 cohorts 1 and 2 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment arm, Part 2 cohorts 3-7 - ORR by cohort
Secondary: Part 1 - Disease control rate (DCR) by dose level, Part 1 - ORR by dose level, Part 2 all cohorts - (PFS) by cohort and treatment arm, Part 2 all cohorts - DCR by cohort and treatment arm, Part 2 all cohorts - Duration of response (DOR) by cohort and treatment arm, Part 2 all cohorts - Overall survival (OS) by cohort and treatment arm, Part 2 cohorts 3-7 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment arm, Part 2 cohorts 3-7 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment arm
Oncology